Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

• Stephanie J. Nahas,
• Steffen Naegel,
• Joshua M. Cohen,
• Xiaoping Ning,
• Lindsay Janka,
• Verena Ramirez Campos,
• Lynda J. Krasenbaum,
• Dagny Holle-Lee,
• David Kudrow,
• Christian Lampl

Affiliations

Stephanie J. Nahas

Department of Neurology, Thomas Jefferson University

Steffen Naegel

Department of Neurology, University Hospital Halle (Saale) and University Halle-Wittenberg

Joshua M. Cohen

Teva Pharmaceutical Industries

Xiaoping Ning

Teva Pharmaceutical Industries

Lindsay Janka

Teva Pharmaceutical Industries

Verena Ramirez Campos

Teva Pharmaceutical Industries

Lynda J. Krasenbaum

Teva Pharmaceutical Industries

Dagny Holle-Lee

Department of Neurology and Westgerman Headache Center Essen, University Hospital

David Kudrow

California Medical Clinic for Headache

Christian Lampl

Headache Medical Centre